Nauman Wazir, Shafqat-ur Rehman, Muhammad Arshad, Muhammad Zubair Wazir, Shehriyar Khan, Muhammad Saqib Ullah.
Effect of Empagliflozin on Liver Enzymes of patients in Non-Alcoholic Steatohepatitis in Type 2 Diabetes Mellitus.
J Gandhara Med Dent Sci Jan ;10(2):30-3.

OBJECTIVES: To assess the effect of 10 mg and 25 mg once daily Empagliflozin on liver enzymes of patients of non-alcoholic steatohepatitis in patients of type 2 diabetes mellitus (T2DM). METHODOLOGY: The study design was open labelled, randomized clinical trial. Thirty three adult patients of  Type 2 diabetes mellitus (T2DM) who were already on 2000 mg of metformin and 100 mg of Sitagliptin and were having suboptimal glycemic control (HBA1C > 7% <12%), had elevated Alanine Transaminase (ALT) levels and had ultrasonographic features consistent with non-alcoholic fatty liver disease (NAFLD) were randomized to  three groups. One group received 10 mg Empagliglozin as add-on treatment (Group A), the second group received 25 mg of Empagliflozin (Group B) as an additional treatment, and the third group continued with the previous medications without any additional treatment (Group C). HbA1C levels and ALT levels of all the three groups were taken at baseline and at 12 weeks.. RESULTS: Total patients and their mean ages in group A, B and C were 10, 12 and 11, and 52.40 ±4.24 years, 52.42 ± 5.27 years and 52.34 ± 4.37 years, respectively. There was a statistically significant (p > 0.00) decrease mean ALT levels in Group A and B both 12 weeks post treatment as compared to pre-treatment levels. In group C, however, there was no statistically significant decrease in ALT levels after 12 weeks of follow up.. CONCLUSION: Empagliflozin in both 10mg and 25 mg once daily doses cause statistically significant reduction in ALT levels in patients with NASH associated with T2DM.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com